Search

Your search keyword '"Altamura, Claudia"' showing total 558 results
Start Over Author "Altamura, Claudia"
558 results on '"Altamura, Claudia"'

5. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

8. Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study

Author

Vernieri, Fabrizio, Brunelli, Nicoletta, Guerzoni, Simona, Iannone, Luigi Francesco, Baraldi, Carlo, Rao, Renata, Schiano di Cola, Francesca, Ornello, Raffaele, Cevoli, Sabina, Lovati, Carlo, Albanese, Maria, Perrotta, Armando, Cetta, Ilaria, Rossi, Sergio Soeren, Taranta, Valentina, Filippi, Massimo, Geppetti, Pierangelo, Sacco, Simona, and Altamura, Claudia

Published
2023
Full Text
View/download PDF

9. Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

10. Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: An Italian multicenter study

Author

Viticchi, Giovanna, Di Stefano, Vincenzo, Altamura, Claudia, Falsetti, Lorenzo, Torrente, Angelo, Brunelli, Nicoletta, Salvemini, Sergio, Alonge, Paolo, Bartolini, Marco, Di Felice, Chiara, Adragna, Maria Stella, Moroncini, Gianluca, Vernieri, Fabrizio, Brighina, Filippo, and Silvestrini, Mauro

Published
2024
Full Text
View/download PDF

11. OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

Author

Altamura, Claudia, Ornello, R., Ahmed, F., Negro, A., Miscio, A. M., Santoro, A., Alpuente, A., Russo, A., Silvestro, M., Cevoli, S., Brunelli, N., Grazzi, L., Baraldi, C., Guerzoni, S., Andreou, A. P., Lambru, G., Frattale, I., Kamm, K., Ruscheweyh, R., Russo, M., Torelli, P., Filatova, E., Latysheva, N., Gryglas-Dworak, A., Straburzynski, M., Butera, C., Colombo, B., Filippi, M., Pozo-Rosich, P., Martelletti, P., Sacco, S., and Vernieri, F.

Published
2023
Full Text
View/download PDF

12. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience

Author

Altamura, Claudia, Brunelli, Nicoletta, Marcosano, Marilena, Aurilia, Cinzia, Egeo, Gabriella, Lovati, Carlo, Favoni, Valentina, Perrotta, Armando, Maestrini, Ilaria, Schiano Di Cola, Francesca, d’Onofrio, Florindo, Finocchi, Cinzia, Bertuzzo, Davide, Bono, Francesco, Ranieri, Angelo, Albanese, Maria, Messina, Roberta, Doretti, Alberto, Di Piero, Vittorio, Cevoli, Sabina, Barbanti, Piero, and Vernieri, Fabrizio

Published
2022
Full Text
View/download PDF

17. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

Author

Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Altamura, Claudia, d’Onofrio, Florindo, Finocchi, Cinzia, Albanese, Maria, Aguggia, Marco, Rao, Renata, Zucco, Maurizio, Frediani, Fabio, Filippi, Massimo, Messina, Roberta, Cevoli, Sabina, Carnevale, Antonio, Fiorentini, Giulia, Messina, Stefano, Bono, Francesco, Torelli, Paola, Proietti, Stefania, Bonassi, Stefano, and Vernieri, Fabrizio

Published
2022
Full Text
View/download PDF

19. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study

Author

Ornello, Raffaele, Baraldi, Carlo, Guerzoni, Simona, Lambru, Giorgio, Andreou, Anna P., Raffaelli, Bianca, Gendolla, Astrid, Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Cevoli, Sabina, Favoni, Valentina, Vernieri, Fabrizio, Altamura, Claudia, Russo, Antonio, Silvestro, Marcello, Valle, Elisabetta Dalla, Mancioli, Andrea, Ranieri, Angelo, Alfieri, Gennaro, Latysheva, Nina, Filatova, Elena, Talbot, Jamie, Cheng, Shuli, Holle, Dagny, Scheffler, Armin, Nežádal, Tomáš, Čtrnáctá, Dana, Šípková, Jitka, Matoušová, Zuzana, Casalena, Alfonsina, Maddestra, Maurizio, Viola, Stefano, Affaitati, Giannapia, Giamberardino, Maria Adele, Pistoia, Francesca, Reuter, Uwe, and Sacco, Simona

Published
2022
Full Text
View/download PDF

22. Acute medications' intake for migraine: a one-year report in patients undergoing first evaluation at a third level Italian headache center.

Author

Bonura, Adriano, Alesina, Alessandro, Sapio, Elisabetta, Brunelli, Nicoletta, Marcosano, Marilena, Altamura, Claudia, and Vernieri, Fabrizio

Subjects
MEDICATION overuse headache, PRIMARY headache disorders, MIGRAINE, ANTI-inflammatory agents, MONOCLONAL antibodies, NONSTEROIDAL anti-inflammatory agents
Abstract

Background: Headache disorders, particularly primary headaches like migraine and tension-type headache, still remain underdiagnosed and undertreated despite their high prevalence and significant impact on quality of life. In recent years, several specific medications targeting key pathways in the pathophysiology of migraine have been developed. Despite this advancement, numerous studies indicate that non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics remain the most commonly used drugs. This study focused on the use of NSAIDs and simple analgesics as acute treatments for migraine among patients at a tertiary headache center. Methods: A retrospective observational study was conducted at the Fondazione Policlinico Universitario Campus Bio-Medico throughout 2022. Data were collected on the type and frequency of headaches, the usage and dosage of NSAIDs and other medications, and changes in their use at follow-up visits. Statistical analyses were performed to evaluate the efficacy and determinants of NSAID consumption and headache frequency changes. Results: Two hundred and eightythree patients diagnosed with migraine undergoing their first examination at our center were enrolled. Initially, 58.7% of patients used NSAIDs or simple analgesics, which decreased to 46.6% 3 months after, while triptan use increased from 65.1 to 72.8%. Changes in prophylactic therapies were significantly associated with a decrease in NSAID intake (W = 834.000, p = 0.004) and in headache frequency (W = 5960.5, p = 0.003). Specifically, the addition of topiramate or amitriptyline was associated with a reduction in NSAID use and headache frequency. Even pain freedom after the intake of NSAIDs improved from 55.2 to 79.4% of cases at follow-up. Conclusion: The study highlights the importance of appropriate diagnosis and tailored treatment strategies in the management of primary headaches. It underscores the need for specialized care to enhance treatment efficacy and patient outcomes, demonstrating that adjustments in prophylactic therapy can significantly reduce NSAID intake and improve headache care. This reinforces the role of tertiary headache centers in providing specialized care that can adapt treatments to individual patient needs and improve overall headache management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study.

Author

Zanandrea, Laura, Messina, Roberta, Cetta, Ilaria, Genovese, Federica, Guerrieri, Simone, Vernieri, Fabrizio, Altamura, Claudia, Cevoli, Sabina, Favoni, Valentina, Colombo, Bruno, and Filippi, Massimo

Subjects
MEDICATION abuse, IMPACT testing, MIGRAINE, PEPTIDES, CALCITONIN
Abstract

Background and Purpose: Fremanezumab, a monoclonal antibody targeting the calcitonin gene‐related peptide for migraine prevention, is available in monthly (225 mg) and quarterly (675 mg) doses. Previous studies showed efficacy and safety for both regimens, but a real‐life comparison is lacking. This study aimed to compare the effectiveness and safety of monthly and quarterly fremanezumab in a real‐life setting. Methods: This Italian, prospective, multicenter study enrolled 95 migraine patients. During a 3‐month treatment period, patients received either monthly or quarterly fremanezumab (49 monthly, 46 quarterly). A 6‐month treatment period involved 79 patients (43 monthly, 36 quarterly). Monthly headache (MHD) and migraine days (MMD), number of days (AMD) and pills (AMP) of acute medication intake, and Headache Impact Test (HIT‐6), Migraine Disability Assessment (MIDAS) test, and Numeric Rating Scale (NRS) scores were recorded at baseline and after 3 and 6 months of treatment. Adverse events (AEs), responder rates, and medication overuse were also investigated. Results: Both monthly and quarterly treatments led to significant reductions in MMD, MHD, AMP, AMD, HIT‐6, MIDAS, and NRS scores after 3 and 6 months. The monthly regimen exhibited a slightly greater reduction in MMD and MHD after the first quarter, with no significant difference observed after 6 months. The most common AE was transient injection‐site reaction, without between‐group differences. Responder rates and resolution of medication overuse did not significantly differ between the groups. Conclusions: Both monthly and quarterly regimens were effective and safe, with a tendency for an advantage of the monthly regimen only in the first quarter of treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Impact of carotid stenosis on the outcome of stroke patients submitted to reperfusion treatments: a narrative review.

Author

Viticchi, Giovanna, Falsetti, Lorenzo, Altamura, Claudia, Di Felice, Chiara, Vernieri, Fabrizio, Bartolini, Marco, and Silvestrini, Mauro

Subjects
CAROTID artery stenosis, STROKE patients, REPERFUSION, THERAPEUTIC complications
Abstract

Intravenous thrombolysis (IT) and mechanical thrombectomy (MD) are the two interventional approaches that have changed the outcome of patients with acute ischemic stroke (AIS). Ipsilateral and contralateral carotid stenosis (ICS, CCS) play an important role in regulating cerebral hemodynamics, both in chronic and acute situations such as AIS. Several studies have explored their role in the incidence and severity of stroke, but very few have investigated the possible impact of ICS and CCS on the efficacy of interventional procedures. The purpose of this review was to I) highlight the incidence and prevalence of carotid stenosis (CS); II) assess the impact of ICS and CCS on cerebral hemodynamics; III) evaluate the effect of carotid stenosis on the efficacy of interventional therapies (IT and MT) for AIS; and IV) report therapeutic complications related to CS. We searched PubMed/Medline for case reports, reviews, and original research articles on English-language review topics during the period from January 1, 2000 to October 1, 2023. CS is associated with 15–20 % of the total number of AIS. ICS and CCS had a negative influence on both cerebral hemodynamics before AIS and outcome after interventional procedures (IT, MT alone or in bridging). Available data on cerebral hemodynamics and efficacy of interventional therapies for AIS suggest a negative role of CS. Therefore, early diagnosis of CS may be considered relevant to preventive and post-stroke treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Increased Prevalence of Headaches and Migraine in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Insights from an Italian Cohort Study

Author

Marino, Annalisa, primary, Currado, Damiano, additional, Altamura, Claudia, additional, Vomero, Marta, additional, Berardicurti, Onorina, additional, Corberi, Erika, additional, Kun, Lyubomyra, additional, Pilato, Andrea, additional, Biaggi, Alice, additional, Genovali, Irene, additional, Bearzi, Pietro, additional, Minerba, Marco, additional, Orlando, Antonio, additional, Trunfio, Francesca, additional, Quadrini, Maria, additional, Salvolini, Chiara, additional, Di Corcia, Letizia Pia, additional, Saracino, Francesca, additional, Giacomelli, Roberto, additional, and Navarini, Luca, additional

Published
2024
Full Text
View/download PDF

31. Delirium in heart failure

Author

Correale, Michele, Altamura, Mario, Carnevale, Raffaella, Tricarico, Lucia, Malerba, Stefania, Gallotta, Anna Maria, Altamura, Claudia, Perrella, Michela, Di Biase, Matteo, Bellomo, Antonello, and Brunetti, Natale Daniele

Published
2020
Full Text
View/download PDF

33. Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.

Author

Montisano, Danilo Antonio, Giossi, Riccardo, Canella, Mattia, Altamura, Claudia, Marcosano, Marilena, Vernieri, Fabrizio, Raggi, Alberto, and Grazzi, Licia

Subjects
SUMATRIPTAN, MIGRAINE, MONOCLONAL antibodies, HEADACHE, ALLODYNIA, BOTULINUM toxin, DISABILITIES
Abstract

Background: Chronic migraine (CM) is a disabling and hard-to-treat condition, associated with high disability and high cost. Among the preventive treatments, botulinum toxin A (BoNT-a) and monoclonal antibodies against the calcitonin gene-related protein (anti-CGRP mAbs) are the only disease-specific ones. The assessment of the disease burden is complex, and among others, tools such as the allodynia symptoms checklist (ASC-12) and headache impact test (HIT-6) are very useful. This exploratory study analysed the impact of these two therapies on migraine burden. Methods: The RAMO study was a multicentre, observational, retrospective investigation conducted in two headache centres: the Fondazione IRCCS Istituto Neurologico Carlo Besta (Milan) and the Fondazione Policlinico Campus Bio-Medico (Rome). This study involved patients with chronic migraine treated with mAbs or BoNT-A. We conducted a subgroup exploratory analysis on HIT-6 and ASC-12 scores in the two groups. The Wilcoxon rank-sum test, Fisher's exact test, and ANOVA were performed. Results: Of 126 patients, 36 on mAbs and 90 on BoNT-A had at least one available follow-up. mAbs resulted in a mean reduction of −11.1 and −11.4 points, respectively, in the HIT-6 at 6 and 12 months, while BoNT-A was reduced −3.2 and −3.6 points, respectively; the mAbs arm resulted in mean reductions in ASC-12 at 6 and 12 months of follow-up of −5.2 and −6.0 points, respectively, while BoNT-A showed lesser mean changes of −0.5 and −0.9 points, respectively. The adjusted analysis confirmed our results. Conclusions: In this exploratory analysis, anti-CGRP mAbs showed superior effectiveness for HIT-6 and ASC12 compared to BoNT-A. Reductions in terms of month headache days (MHD), migraine disability assessment test (MIDAS), and migraine acute medications (MAM) were clinically relevant for both treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study

Author

Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Lovati, Carlo, Bertuzzo, Davide, d'Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Schiano Di Cola, Francesca, Ranieri, Angelo, Colombo, Bruno, Bono, Francesco, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero, GARLIT Study Group, Filippi, Massimo, Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Lovati, Carlo, Bertuzzo, Davide, D'Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Schiano Di Cola, Francesca, Ranieri, Angelo, Colombo, Bruno, Bono, Francesco, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero, GARLIT Study, Group, and Filippi, Massimo

Subjects
Adult, Male, medicine.medical_specialty, Migraine Disorders, Triptans, Calcitonin gene-related peptide, Antibodies, Monoclonal, Humanized, Chronic Migraine, Double-Blind Method, Internal medicine, medicine, galcanezumab, Humans, Mass index, CGRP, real-life, Prospective Studies, Rapid response, business.industry, Middle Aged, medicine.disease, Comorbidity, Treatment Outcome, Italy, Neurology, Migraine, Female, Observational study, monoclonal antibodies, Neurology (clinical), chronic migraine, business, medicine.drug
Abstract

Background and purpose A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) and diverse preventive treatment failures. This prospective, observational, multicenter real-life study aimed at investigating the effectiveness of galcanezumab in the first 3 months of treatment of CM patients at 14 Italian headache centers. Methods All consecutive adult patients with CM diagnosis with the clinical indication for galcanezumab were considered. We collected patients' baseline characteristics, monthly headache days, monthly painkiller intake, migraine clinical characteristics, and disability scale scores during a 1-month run-in period (baseline) and the first 3 months of therapy. Possible predictive factors of treatment were considered. Results A total of 156 patients (82.4% female, aged 47.3 +/- 12.3 years) were enrolled. The 65 (41.7%) patients with a consecutive >= 50% response rate (RR) in the 3 months of therapy presented a lower body mass index (p = 0.004) and more frequently presented unilateral migraine pain (p = 0.002) and good response to triptans (p = 0.003). Persistent conversion from CM to episodic migraine was observed in 55.8% (87/156) of patients. They more frequently presented a good response to triptans (p = 0.003) and unilateral pain (p = 0.046). At baseline, 131 of 156 (83.9%) patients presented medication overuse (MO). Of these, 61.8% (81/131) no longer displayed MO consistently during the 3 months. These patients were more frequently responders to triptans (p = 0.002) and less frequently suffered from gastrointestinal comorbidity (p = 0.007). Conclusions Unilateral pain, good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab in CM patients.

Published
2021

42. Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review

Author

Altamura,Claudia, Brunelli,Nicoletta, Marcosano,Marilena, Alesina,Alessandro, Fofi,Luisa, Vernieri,Fabrizio, Altamura,Claudia, Brunelli,Nicoletta, Marcosano,Marilena, Alesina,Alessandro, Fofi,Luisa, and Vernieri,Fabrizio

Abstract

Claudia Altamura,1,2 Nicoletta Brunelli,1,2 Marilena Marcosano,1,2 Alessandro Alesina,1,2 Luisa Fofi,1,2 Fabrizio Vernieri1,2 1Fondazione Policlinico Universitario Campus Bio-Medico, Roma, 00128, Italy; 2Unit of Headache and Neurosonology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, ItalyCorrespondence: Claudia Altamura, Unit of Headache and Neurosonology, Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, Via Alvaro del Portillo, 200, Roma, 00128, Italy, Tel +3906225411270, Fax +3906225411936, Email c.altamura@policlinicocampus.itAbstract: The new Calcitonin Gene-Related Peptide (CGRP)-targeted therapies have proven high efficacy and tolerability in episodic and chronic migraine. Eptinezumab is a humanized monoclonal antibody that selectively binds CGRP with high affinity. Eptinezumab was approved by the Food and Drug Administration on February 21st, 2020, for the preventive treatment of migraine in adults. It is administered intravenously over 30 minutes with a standard dose of 100 mg and has a T-max of 30 minutes-1 hour and a half-life of 27 days. These pharmacological properties allow for a very rapid onset of effect and a quarterly administration. It is the first time that a preventive treatment for migraine can be offered as an intravenous administration. As the range of therapeutic possibilities in migraine is expanding, the treatment process must include common decision-making, where physicians should explain in detail to patients the different characteristics of treatment options beyond efficacy and side effects. Patients can now express a preference on a range of opportunities: pharmacological versus non-pharmacological approaches, route of administration, frequency of administration, efficacy, rapidity, side effects, costs, the possibility of titration or dosing, and durability of effectiveness at suspension. Also, patient preferences can be influenced by age, country, migraine severity, and

Published
2023

43. Stroke territory and atherosclerosis in ischemic stroke patients with a history of migraine with aura

Author

Altamura, Claudia, primary, Viticchi, Giovanna, additional, Rizzo, Angelo Cascio, additional, Maggio, Paola, additional, Brunelli, Nicoletta, additional, Marcosano, Marilena, additional, Lazzaro, Vincenzo Di, additional, Fiacco, Fabrizio, additional, Agostoni, Elio Clemente, additional, Silvestrini, Mauro, additional, and Vernieri, Fabrizio, additional

Published
2023
Full Text
View/download PDF

47. OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

Author

Altamura, Claudia, primary, Ornello, R., additional, Ahmed, F., additional, Negro, A., additional, Miscio, A. M., additional, Santoro, A., additional, Alpuente, A., additional, Russo, A., additional, Silvestro, M., additional, Cevoli, S., additional, Brunelli, N., additional, Grazzi, L., additional, Baraldi, C., additional, Guerzoni, S., additional, Andreou, A. P., additional, Lambru, G., additional, Frattale, I., additional, Kamm, K., additional, Ruscheweyh, R., additional, Russo, M., additional, Torelli, P., additional, Filatova, E., additional, Latysheva, N., additional, Gryglas-Dworak, A., additional, Straburzynski, M., additional, Butera, C., additional, Colombo, B., additional, Filippi, M., additional, Pozo-Rosich, P., additional, Martelletti, P., additional, Sacco, S., additional, and Vernieri, F., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results